middle.news
How Argent BioPharma’s A$17.8M Loss Fuels Its EU Drug Expansion
4:38am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Argent BioPharma’s A$17.8M Loss Fuels Its EU Drug Expansion
4:38am on Saturday 30th of August, 2025 AEST
Key Points
Net loss of A$17.84 million, slight increase from prior year
Revenue declined 80% to A$0.18 million due to focus on core activities
CimetrA® Phase IIb trial confirms safety and anti-inflammatory potential
CannEpil™ and CogniCann™ gain prescription approvals in Germany
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE